Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT03556228
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT03556228 ↗
- Recruiting
- VM Oncology, LLC
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03556228 (VMD-928; VMD-928 plus pembrolizumab in TrkA overexpression driven solid tumors or lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03556228 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Head and Neck Carcinoma; Adenoid Cystic Carcinoma; Lung Cancer; Non-Small Cell Lung Cancer; Pancreatic Cancer; Mesothelioma; Esophageal Cancer; Any Solid Tumors Progressed After a Prior Immunotherapy; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma HNSCC; Salivary Gland Carcinomas; Head and Neck Cancers - Salivary Gland; Head and Neck Cancers - Nasopharyngeal; Head and Neck Cancers - Throat; Small Cell Lung Cancer ( SCLC ); Lung Cancer (Locally Advanced or Metastatic); Head and Neck Cancers - Tonsils; Head and Neck Cancers Hypopharynx; Head and Neck Cancers Larynx; Head and Neck Cancers Lip; Head and Neck Cancers Nasopharynx; Head and Neck Cancers Oral Cavity; Head and Neck Cancers; Head and Neck Cancers Oropharynx; Head and Neck Cancers Trachea
- Interventions
- VMD-928 100 mg Tablet; VMD-928 Tablet and Pembrolizumab (200 mg)
- Arms
- VMD-928 monotherapy · Experimental
- Combination Therapy · Experimental
- Enrollment
- 242 (estimated)
- Primary outcomes
- Number and severity of treatment-emergent Adverse Events (Phase 1)
- To determine the recommended Phase 2 dose for VMD-928 (Phase 1)
- To determine the RP2D of VMD-928 in combination with pembrolizumab (Phase 1)
- Antitumor activity of VMD-928 in subjects with TrkA-driven tumors (Phase 2)
- Antitumor activity of VMD-928 in combination with pembrolizumab in subjects with TrkA-driven tumors (Phase 2)
- Sponsor
- VM Oncology, LLC
- Start
- Jun 8, 2018
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03556228 · updated Nov 4, 2026